MADI unveiled MADI-DT at CES 2026, a generative AI platform creating synthetic patients to replace p...
The AMW Read
The launch of MADI-DT updates the baseline for Vertical AI in healthcare by demonstrating a shift toward synthetic data/digital twins as a viable replacement for placebo groups in clinical R&D.
NoveltySignificance
Healthcare & Bio Β· Player Map
MADI unveiled MADI-DT at CES 2026, a generative AI platform creating synthetic patients to replace placebo groups in clinical trials. Using 40,000 cases of high-fidelity Asian clinical data, the system reduces recruitment by 25% and saves $2.3 million per trial. This tackles the global diversity gap while shortening timelines by over six months. Digital twins are becoming a core regulatory standard for pharmaceutical R&D and regional market entry.
